TOKYO, Oct 21 (Reuters) – Japan’ Shionogi & Co Ltd (4507.T) mentioned on Wednesday it had began a Part II/III medical trial for its COVID-19 vaccine candidate.
The trial for the recombinant protein-based vaccine will happen in Japan and follows a Part I trial within the nation, Shionogi mentioned in a press release. The corporate may also put together to conduct a number of trials globally, it mentioned.
Medicines often should go three phases of medical trials earlier than they are often assessed for approval by regulators.
Individually, Daiichi Sankyo Co (4568.T) mentioned it deliberate to begin a Part II trial for its COVID-19 vaccine candidate subsequent month.
The Japanese drugmaker is aiming for commercialization of the mRNA-type vaccine, often called DS-5670, in 2022, it mentioned in a press release.
Reporting by Rocky Swift Enhancing by Jacqueline Wong and Mark Potter
Our Requirements: The Thomson Reuters Trust Principles.
0 Comments